Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

videos

Videos
Should You Stop TKI Treatment for CML in Major Molecular Response?
12/23/2019
Sangmin Lee, MD, discusses whether or not you should stop TKI treatment in patients with CML in major molecular response.
Sangmin Lee, MD, discusses whether or not you should stop TKI treatment in patients with CML in major molecular response.
Sangmin Lee, MD, discusses...
12/23/2019
Oncology
Videos
Treatment Options for Patients With Mantle Cell Lymphoma
12/05/2019
Michael Williams, MD, discusses treatment approaches for a variety of patients with mantle cell lymphoma.
Michael Williams, MD, discusses treatment approaches for a variety of patients with mantle cell lymphoma.
Michael Williams, MD, discusses...
12/05/2019
Oncology
Videos
What is the Best Treatment Approach for Patients With MM Ineligible for Transplant?
11/13/2019
Vincent Rajkumar, MD, explains treatment approaches for patients with newly-diagnosed MM ineligible for transplant.
Vincent Rajkumar, MD, explains treatment approaches for patients with newly-diagnosed MM ineligible for transplant.
Vincent Rajkumar, MD, explains...
11/13/2019
Oncology
Videos
CAR T-Cell Therapy: Where Do We Stand in 2019?
11/13/2019
Thomas Kipps, MD, PhD, gives an update on the development of CAR T-cell therapy at the 2019 Lymphoma & Myeloma Congress.
Thomas Kipps, MD, PhD, gives an update on the development of CAR T-cell therapy at the 2019 Lymphoma & Myeloma Congress.
Thomas Kipps, MD, PhD, gives an...
11/13/2019
Oncology
Videos
Novel Agents for Treating Older Patients With CLL
11/13/2019
Jennifer Woyach, MD, discusses treatment options for older patients with CLL and why treating older patients differs from treating younger patients.
Jennifer Woyach, MD, discusses treatment options for older patients with CLL and why treating older patients differs from treating younger patients.
Jennifer Woyach, MD, discusses...
11/13/2019
Oncology
Videos
Managing Venetoclax Resistance in CLL
11/12/2019
Matthew S. Davids, MD, MMSc, discusses venetoclax resistance in CLL and how to manage patients resistant to the drug.
Matthew S. Davids, MD, MMSc, discusses venetoclax resistance in CLL and how to manage patients resistant to the drug.
Matthew S. Davids, MD, MMSc,...
11/12/2019
Oncology
Videos
Who Should Receive CAR T-Cell Therapy for DLBCL?
11/12/2019
Craig Sauter, MD, explains which patients should receive CAR T-cells for DLBCL.
Craig Sauter, MD, explains which patients should receive CAR T-cells for DLBCL.
Craig Sauter, MD, explains which...
11/12/2019
Oncology
Videos
Should Monoclonal Antibodies Be Used in the Front-Line Setting for MM?
11/12/2019
Ajai Chari, MD, explains whether anti‑CS1, anti‑CD38, and bispecifics, should be used in the frontline setting for multiple myeloma.
Ajai Chari, MD, explains whether anti‑CS1, anti‑CD38, and bispecifics, should be used in the frontline setting for multiple myeloma.
Ajai Chari, MD, explains whether...
11/12/2019
Oncology
Videos
Treating CLL That Progress With BTK Inhibitor Therapy
11/12/2019
Richard Furman, MD, explains how best to control CLL patients who progress on BTK inhibitor therapy.
Richard Furman, MD, explains how best to control CLL patients who progress on BTK inhibitor therapy.
Richard Furman, MD, explains how...
11/12/2019
Oncology
Videos
Indications for Transplant in Low/Intermediate Risk MDS
11/07/2019
Koen van Besien, MD, PhD, discusses data on the indications for transplant for patients with low and intermediate‑grade MDS.
Koen van Besien, MD, PhD, discusses data on the indications for transplant for patients with low and intermediate‑grade MDS.
Koen van Besien, MD, PhD,...
11/07/2019
Oncology

Advertisement

Advertisement

About

For nearly 2 decades, the Lymphoma, Leukemia & Myeloma Congress (formerly the Lymphoma & Myeloma Congress) has been recognized around the world as the most respected forum for industry-leading hematologic research.

It’s where interdisciplinary specialists convene to explore the controversial and the complex, the emerging and the exciting, and discuss, debate, and discover along the way.

This program features 4 days of comprehensive learning as we analyze emerging data, discover innovative treatment methods, and get a glimpse into the future of lymphoma, myeloma, and leukemia disorders.

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use